Picture of Nexien Biopharma logo

NXEN Nexien Biopharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-0.4%
3m+7.17%
6m-16.53%
1yr-37.24%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-55.01%
50d MA-5.44%
200d MA-12.69%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Nexien Biopharma EPS forecast chart

Profile Summary

Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

Directors

    Last Annual
    June 30th, 2023
    Last Interim
    March 31st, 2024
    Incorporated
    February 25th, 2008
    Public Since
    July 11th, 2001
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq
    Shares in Issue
    67,472,196

    NXEN Share Price Performance

    Upcoming Events for NXEN

    Q1 2025 Nexien Biopharma Inc Earnings Release

    Q2 2025 Nexien Biopharma Inc Earnings Release

    Similar to NXEN

    Picture of Acusphere logo

    Acusphere

    us flag iconPink Sheets on Nasdaq

    Picture of Adorbs logo

    Adorbs

    us flag iconPink Sheets on Nasdaq

    Picture of Agentix logo

    Agentix

    us flag iconPink Sheets on Nasdaq

    Picture of Agrios Global Holdings logo

    Agrios Global Holdings

    us flag iconPink Sheets on Nasdaq

    Picture of Aida Pharmaceuticals logo

    Aida Pharmaceuticals

    us flag iconPink Sheets on Nasdaq

    FAQ